Cargando…
Are NOACs as safe and efficient as VKA regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: ‘Are NOACs as safe and efficient as vitamin K antagonist regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within...
Autores principales: | Magro, Pedro Lamares, Sousa-Uva, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070514/ https://www.ncbi.nlm.nih.gov/pubmed/34977926 http://dx.doi.org/10.1093/icvts/ivab363 |
Ejemplares similares
-
Oral anticoagulation following bioprosthetic SAVR in patients with atrial fibrillation: what’s the current status of NOACs?
por: Milojevic, Milan, et al.
Publicado: (2022) -
Standalone epicardial left atrial appendage exclusion for thromboembolism prevention in atrial fibrillation
por: Cartledge, Richard, et al.
Publicado: (2021) -
Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis†
por: Klautz, Robert J.M., et al.
Publicado: (2017) -
New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
por: Rutherford, Ole-Christian Walter, et al.
Publicado: (2018) -
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
por: Escobar Cervantes, Carlos, et al.
Publicado: (2022)